Conferences - Results from #7440

ASCO 2018: Phase II Safety and Tolerability Study of Radium-223 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: CTRIAL-IE (ICORG) 13-21 June 3, 2018

ASCO 2018: Pembrolizumab Plus Enzalutamide in Metastatic Castration Resistant Prostate Cancer: Extended Follow Up June 3, 2018

ASCO 2018: A Phase 3, Randomized, Open-label Study of Nivolumab Combined with Cabozantinib vs Sunitinib in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma June 3, 2018

ASCO 2018: PROSPER: A Phase III Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy June 3, 2018

ASCO 2018: PECULIAR: An Open Label, Multicenter, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab and Epacadostat, Preceding Radical Cystectomy, for Patients with Muscle-invasive Urothelial Bladder Cancer June 3, 2018

ASCO 2018: Updated Results from the Enfortumab Vedotin Phase 1 (EV-101) Study in Patients with Metastatic Urothelial Cancer June 3, 2018

ASCO 2018: First Results from the Primary Analysis Population of the Phase 2 Study of Erdafitinib in Patients with Metastatic or Unresectable Urothelial Carcinoma and FGFR Alterations June 3, 2018

ASCO 2018: Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade June 3, 2018

ASCO 2018: Lutetium-177 PSMA617 Theranostics In Metastatic Castrate-Resistant Prostate Cancer: Interim Results of a Phase II Trial June 3, 2018

ASCO 2018: A Randomized Phase 2 Trial of Pazopanib vs. Temsirolimus in Patients with Advanced Clear-Cell Renal Cell Carcinoma with Intermediate or Poor-risk Disease (The TemPa Trial) June 3, 2018

ASCO 2018: SPIRE: A Phase 1b/Randomized 2a Open Label Clinical Trial Combining Guadecitabine (SGI-110) with Cisplatin and Gemcitabine Chemotherapy for Solid Malignancies Including Bladder Cancer June 3, 2018

ASCO 2018: Lenvatinib + Pembrolizumab in Patients with Renal Cell Carcinoma: Updated Results June 3, 2018

ASCO 2018: Pembrolizumab Monotherapy as First-Line Therapy in Advanced Clear Cell RCC: Results from Cohort A of KEYNOTE-427 June 3, 2018

ASCO 2018: Combination of Niclosamide to Target Androgen Receptor Variant 7 and Abiraterone to Target Androgen June 3, 2018

ASCO 2018: Results from the PROSPER Study: HRQoL Deterioration and Pain Progression in Men with Non-Metastatic Castration-Resistant Prostate Cancer June 3, 2018

ASCO 2018: KEYNOTE-046: ADXS-PSA plus Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer June 3, 2018

ASCO 2018: Atezolizumab in First-Line Cisplatin-Ineligible or Platinum Treated Locally Advanced or Metastatic Urothelial Cancer: Long-Term Efficacy from Phase 2 Study IMvigor210 June 3, 2018

ASCO 2018: Timing of Androgen Deprivation Therapy for Prostate Cancer Patients After Radiation: Planned Combined Analysis of Two Randomized Phase 3 Trials June 3, 2018

ASCO 2018: BMS-986205, an IDO1 Inhibitor, in Combination with Nivolumab: Updated Safety Across all Tumor Cohorts and Efficacy in Patients with Advanced Bladder Cancer June 3, 2018

ASCO 2018: Phase III Trial Finds Many People with Advanced Kidney Cancer Do Not Need Surgery June 3, 2018

Page 373 of 590